Coronavirus impact: 20 July - positive news from a respiratory drug
Assessment of Synairgen’s drug in Covid-19 patients could signal a major breakthrough in the treatment patients.
Synairgen: shares soar of positive Covid-19 test resultsThe share price of Synairgen (LON: SNG), the AIM quoted respiratory drug discovery company, soared over 350% as it announced positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised Covid-19 patients. The trial results showed that SNG001 greatly reduced the number of hospitalised Covid-19 patients who progressed from ‘requiring oxygen’ to ‘requiring ventilation’. It also showed that patients who received SNG001 were at least twice as likely to recover to the point where their everyday activities were not compromised through having been infected by SARS-CoV-2.…